Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the potential cost savings for (a) social care and (b) welfare of making fampridine (fampyra) routinely available on the NHS.

The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service. In developing its recommendations, NICE takes account of all health and publicly funded social care costs and benefits. It does not routinely consider wider societal costs such as the impact on welfare spending.